DermaSensor is the first and only multi-patented FDA-cleared skin cancer detection tool for clinicians who aren’t dermatologists.

Skin cancer is one of the most common cancers in the world, and one of the most survivable when caught early. Melanoma is 99% survivable when found in the earliest stages, and 40% survivable when found late. The difference is a timely referral, and for decades that referral has come down to the naked eye.

Backed by $20M in VC funding, DermaSensor is ending a reliance on visual guesswork. Using AI-powered spectroscopy, our device scans a suspicious lesion with pulses of light and returns an objective risk result in about 30 seconds.

DermaSensor has earned the kind of recognition that's rare in medtech. TIME named us a Best Invention of the Year, and Inc. named us a Best in Innovation honoree alongside Anthropic and Nvidia.

With FDA clearance secured, commercialization is underway. Hundreds of practices across the U.S. are using the device and ten leading health systems are under contract. Contracted devices and annual recurring revenue tripled from year-end 2024 to 2025, with 40,000+ lesions already scanned.

Europe is next. Our device has earned its CE Mark, the certification that authorizes its sale across the EU. We’ve also secured a collaboration with England's National Health Service (NHS), opening the door to the second largest single-payer health system in the world.

For investors, DermaSensor is a proven, FDA-cleared and CE-marked technology in an $8B+ market with no other cleared competitor, backed by $20M and a team that's sold medical device companies to Stryker and GE.

We're building a future where no life is lost to a visible cancer that could have been caught in time.

Nearly 50% of skin cancer referrals can be missed in primary care.

Over 120,000 people die from skin cancer every year around the world, almost always because it was caught too late.

In the US alone, 3 million people are diagnosed annually. Hundreds of thousands undergo invasive surgeries that earlier detection could have prevented, and tens of thousands sadly die. The difference between a routine procedure and a deadly diagnosis comes down to timing.

The biggest obstacle to catching it early is getting to a specialist.

In the US, only about 11,000 dermatologists serve 100 million at-risk people. Across the UK and Europe, the wait to see a dermatologist can stretch months. Between waitlists, time off work, and out-of-pocket costs, and lack of awareness, most people simply never go.

The job of catching skin cancer early falls to the clinicians who see patients for routine physicals. Most primary care clinicians get little dermatology training and often aren't confident evaluating a suspicious mole. Fewer than 9% report using a dermatoscope regularly, a subjective tool that requires extensive training.

Suspicious moles end up being evaluated the same way they were decades ago, by the eye alone. Real cancers get missed, and harmless moles like skin tags get sent to specialists.

Non-dermatologist clinicians have never had an objective detection device available in the exam room.

DermaSensor is equipping clinicians on the front lines with a skin cancer risk detection device that can be used during the same visit it's spotted.

The technology behind DermaSensor was pioneered at Boston University, where Professor Irving Bigio invented the field of Elastic Scattering Spectroscopy.

What was once a 30-pound instrument is now a sleek handheld device that pulses light across 47 wavelengths to capture cellular and sub-cellular features beneath the lesion's surface. The device reads what no eye can.

The algorithm then scores the wavelengths against a database of lesions confirmed by biopsy or board-certified dermatologists.

The patient never feels a thing. They leave the visit with an answer instead of months-long worry.

The objective result also moves patients to take action: clinicians tell us patients are far more likely to follow through on a dermatology referral when they've seen the score for themselves.

Every scan makes DermaSensor smarter and stronger, widening a lead no competitor can close. For years, others have tried to solve skin cancer detection with photos. They all ran into the same problem: a picture only sees the surface.

Several image-based competitors failed to achieve meaningful market adoption or FDA clearance, a previously cleared predecessor exited the market, and consumer melanoma apps faced regulatory roadblocks.

DermaSensor took a different path. Instead of analyzing images, our device reads optical signals from beneath the skin, capturing objective information the naked eye and a camera cannot. The result is a category-defining technology with no direct equivalent today, protected by a 5 patents spanning the core detection method and our proprietary calibration and algorithms.

Our moat gets deeper with every scan: while image-based AI can train on millions of public photos, spectral data can only come from a device in a clinician's hand, and ours is the only one out there.

Primary care physicians are already scanning more than 2,000 lesions a month, and every scan makes the algorithm sharper.

Beyond primary care, the same device already serves concierge medicine, dermatology groups, and medical aesthetics clinics, with reimbursement in place across them.

Because the device runs on software DermaSensor updates remotely, every unit in the field gets better over time.

Four programs are already in development on the same hardware, including a melanoma-optimized algorithm showing early gains and a planned label expansion to nurse practitioners and physician assistants, which would roughly triple the addressable clinician base from 300,000 to nearly 1,000,000.

DermaSensor is in daily use across family medicine, internal medicine, concierge practices, walk-in clinics, and major health systems. Clinicians adopted it first, and now patients ask for it by name, searching our Physician Finder to locate practices that carry the device.

From TIME's Best Inventions to Inc.'s Best in Innovation, DermaSensor has been recognized among the most innovative companies in the world. But the most compelling endorsements come from the exam room.

DermaSensor was co-founded by Dr. Maurice Ferre, a multi-exit medtech CEO. Dr. Ferre scaled MAKO Surgical, the robotic-surgery company, to a $1.65B acquisition by Stryker as CEO. He now chairs DermaSensor's board alongside two other MAKO leaders. They've taken a first-in-class device from launch to exit, and they're doing it again for skin cancer.

CEO and Co-Founder Cody Simmons, a Brown University-trained bioengineer and former Genentech business development leader, was hand-picked by the founders to turn their research project into a company. He built DermaSensor from concept to FDA clearance and a TIME Best Invention of the Year.

DermaSensor’s commercial team has scaled products at Fitbit, Johnson & Johnson, and Qualcomm, and our clinical team has carried the DermaSensor device through pivotal FDA studies. This all-star leadership team has deep expertise in putting new technology into clinicians' hands.

DermaSensor is built on a software-as-a-service model. Clinicians subscribe to the device for $199 to $399 a month based on usage, like a phone plan.

Because there are no large upfront purchase fees to approve, the average sales cycle runs under a month, and every practice that signs on generates recurring revenue.

Subscriptions work because clinicians see returns immediately. Reimbursement is already in place today.

Medicare's national rate pays $198 per procedure, customers average $100+ per patient across payers, and existing billing codes can add roughly $24,600 a year in gross revenue for a single primary care physician. A practice scanning at the average rate covers its subscription 5-10 times over each month.

Revenue comes through three channels:

1) digital direct sales to private practices,

2) executive-led contracts with health systems, and

3) national distribution through reps who will sell devices alongside supplies clinicians already order.

Sales in Europe will follow with commercial partners under the new CE Mark.

DermaSensor launched commercially in May 2024 and is scaling fast. Paid devices tripled in 2025, closing the year at $1M in contracted annual recurring revenue (ARR), with clinicians using each device twice as often as projected. In 2026, contracted revenue is on track to at least triple again.

The next wave of revenue is driven by deals already in place: a national distribution partnership putting 500+ reps behind the device, health system deployments underway, and European commercialization.

The economics compound from there. DermaSensor reaches profitability at 2,500 active devices, and beyond that point every new device adds revenue at a 94% lifetime gross margin.

Forward looking projections are not guaranteed.

DermaSensor's market is every clinician who evaluates suspicious moles but isn't a dermatologist.

In the US alone, that includes 300,000 primary care physicians today, growing to nearly one million clinicians as the device expands to nurse practitioners and physician assistants. Across Europe, it's larger still. DermaSensor is the only FDA-cleared and CE-marked device built for any of them.

When a diagnostic device proves itself with clinicians, the largest names in medtech tend to acquire the company behind it. DermaSensor's own chairman has been on the selling side of that deal before.

Forward looking projections are not guaranteed.

Skin cancer is one of the most common cancers in the world, and the most survivable when it's caught early. Backed by $20M from leading VCs and angels, DermaSensor exists to make catching it early the standard with an FDA-cleared or CE-marked device in every exam room at the front line of care.

The pieces are already in place. Across the U.S., hundreds of practices use the device today, ten health systems are under contract, and two distributors are about to put 500+ reps behind it. In Europe, we’ve laid the foundation for market entry. 1.5M clinicians around the world can’t wait to use DermaSensor, because patients can’t wait.

Almost everyone knows someone who heard "we caught it too late." It doesn't have to be that way. Clinicians are bringing DermaSensor into their exam rooms, and patients are asking for it by name.

Now it's your turn: own a piece of a company working to make sure no one loses their life to a cancer that was visible all along.

Invest in DermaSensor today →